{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:39Z","timestamp":1791876939056,"version":"4.3.4"},"reference-count":250,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.atherosclerosis.2021.11.022","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T20:31:55Z","timestamp":1639081915000},"page":"28-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update"],"prefix":"10.1016","volume":"343","author":[{"given":"Nasreen","family":"Alsayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Almahmeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alnouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Waili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadhim","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zubaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib1","series-title":"Asia-Pacific J. Public Heal.","first-page":"83S","article-title":"Cardiovascular disease in the asia middle east region: global trends and local implications","author":"Ramahi","year":"2010"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrcardio.2017.138","article-title":"Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden","volume":"15","author":"Turk-Adawi","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2016.07.925","article-title":"Dyslipidaemia in the Middle East: current status and a call for action","volume":"252","author":"Al Rasadi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/235101","article-title":"Prevalence of cardiovascular disease and associated risk factors among adult population in the gulf region: a systematic review","author":"Aljefree","year":"2015","journal-title":"Adv. Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/2047487318777079","article-title":"Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international ChoLesterol management practice study (ICLPS)","volume":"25","author":"Danchin","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1570161116666181005125459","article-title":"The gulf familial hypercholesterolemia registry (gulf FH): design, rationale and preliminary results","volume":"18","author":"Al-Rasadi","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5830\/CVJA-2018-054","article-title":"Management of low-density lipoprotein cholesterol levels in South Africa: the International Cholesterol management Practice Study (ICLPS)","volume":"30","author":"Blom","year":"2019","journal-title":"Cardiovasc. J. Afr."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacl.2018.02.003","article-title":"Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf","volume":"12","author":"Al-Rasadi","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOL.0000000000000311","article-title":"Identifying familial hypercholesterolemia in acute coronary syndrome","volume":"27","author":"Gencer","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib11","first-page":"378","article-title":"Pattern of risk factors and management strategies in patients with acute coronary syndrome","volume":"31","author":"Reda","year":"2018","journal-title":"Menoufia Med. J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2016.09.081","article-title":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East","volume":"225","author":"Al Sayed","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib14","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"AMERICAN association OF clinical endocrinologists and AMERICAN college OF endocrinology guidelines for management OF dyslipidemia and prevention OF cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia - full report","volume":"8","author":"Grundy","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO Clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib19","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Tipping","year":"2009","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib21","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib22","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points - a joint consensus statement from the European Atherosclerosis Society and European Fede","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/1570161113666150827125040","article-title":"Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East advisory panel","volume":"13","author":"Al-Ashwal","year":"2015","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2014.11.008","article-title":"Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry","volume":"9","author":"Bamimore","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/1874192401408010088","article-title":"Design and rationale of gulf locals with acute coronary syndrome events (gulf Coast) registry","volume":"8","author":"Zubaid","year":"2014","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5144\/0256-4947.2012.9","article-title":"Baseline characteristics, management practices, and long-term outcomes of middle eastern patients in the second gulf registry of acute coronary events (gulf RACE-2)","volume":"32","author":"AlHabib","year":"2012","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0002-9149(02)02489-X","article-title":"Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)","volume":"90","author":"Steg","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehl196","article-title":"The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004","volume":"27","author":"Mandelzweig","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib31","author":"JBS3"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib32","author":"QRISK"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib33","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Goff","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228031","article-title":"Agreement between cardiovascular disease risk assessment tools: an application to the United Arab Emirates population","volume":"15","author":"Oulhaj","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12872-018-0760-1","article-title":"Should heart age calculators be used alongside absolute cardiovascular disease risk assessment?","volume":"18","author":"Bonner","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jcmg.2017.01.029","article-title":"Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA","volume":"11","author":"Mortensen","year":"2018","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcct.2018.10.001","article-title":"Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"12","author":"Garg","year":"2018","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jcmg.2017.04.014","article-title":"Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC\/AHA cholesterol management guidelines: a cost-effectiveness analysis","volume":"10","author":"Hong","year":"2017","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib39","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib41","first-page":"36","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"339","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib42","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib43","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib46","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib47","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib48","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib50","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"C","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ncpcardio0555","article-title":"Are we lowering LDL cholesterol sufficiently?","volume":"3","author":"Barter","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.20996\/1819-6446-2013-9-1-90-98","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"9","author":"Ference","year":"2013","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib53","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib55","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Production Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib58","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib59","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib60","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Long-term intervention with pravastin in ischaemic disease (LIPID) study group, prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib61","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib62","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib63","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib64","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib65","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib67","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1476-5381.2012.02081.x","article-title":"Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities","volume":"167","author":"Ali","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib68","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib69","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib70","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib72","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib73","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib74","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajcn\/84.2.289","article-title":"Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases","volume":"84","author":"Popkin","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000321527","article-title":"Nutrition transition and cardiovascular disease risk factors in middle East and North Africa countries: reviewing the evidence","volume":"57","author":"Mehio Sibai","year":"2011","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib77","doi-asserted-by":"crossref","DOI":"10.3402\/fnr.v59.27486","article-title":"Association between dietary pattern and risk of cardiovascular disease among adults in the Middle East and North Africa Region: a systematic review","volume":"59","author":"Aljefree","year":"2015","journal-title":"Food Nutr. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib78","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/jn\/138.8.1469","article-title":"Food intake patterns may explain the high prevalence of cardiovascular risk factors among Iranian women","volume":"138","author":"Esmaillzadeh","year":"2008","journal-title":"J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib79","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/CIRCULATIONAHA.106.676379","article-title":"International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries","volume":"116","author":"Balkau","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/2047487312465525","article-title":"Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study","volume":"21","author":"Gehani","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126779","article-title":"The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in north-east of Iran","volume":"10","author":"Sepanlou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib82","author":"Azizi"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib83","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/dmrr.2642","article-title":"Sex and ethnic-origin specific BMI cut points improve prediction of 40-year mortality: the Israel GOH study","volume":"31","author":"Dankner","year":"2015","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib84","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3132\/dvdr.2008.044","article-title":"Optimal cut-points for body mass index, waist circumference and waist-to-hip ratio using the Framingham coronary heart disease risk score in an Arab population of the Middle East","volume":"5","author":"Al-Lawati","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2013.284692","article-title":"Smoking prevalence and cigarette consumption in 187 countries, 1980-2012","volume":"311","author":"Ng","year":"2014","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib86","unstructured":"World Health Organization (WHO), Prevalence of tobacco smoking in 2016, (n.d.). https:\/\/apps.who.int\/gho\/data\/node.sdg.3-a-viz?lang=en (accessed February 12, 2020)."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib87","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib88","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database","volume":"51","author":"Barter","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib89","doi-asserted-by":"crossref","DOI":"10.17987\/icfj.v6i0.160","article-title":"Intensive lipid lowering therapy among patients with coronary artery disease: a middle eastern tertiary care center experience","volume":"6","author":"Garabedian","year":"2016","journal-title":"Int. Cardiovasc. Forum J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib90","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0003319713512414","article-title":"Centralized pan-middle east survey on the undertreatment of hypercholesterolemia: results from the cepheus study in arabian gulf countries","volume":"65","author":"Arafah","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib91","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007995.2014.965774","article-title":"Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf","volume":"30","author":"Al-Rasadi","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib92","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/2047487318777079","article-title":"Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international ChoLesterol management practice study (ICLPS)","volume":"25","author":"Danchin","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","article-title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome","volume":"6","author":"Drexel","year":"2020","journal-title":"Eur. Hear. J. - Cardiovasc. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib94","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/archinte.167.16.1798","article-title":"Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study","volume":"167","author":"Gehi","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17512433.2018.1412826","article-title":"Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs","volume":"11","author":"Lopatowska","year":"2018","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib96","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib97","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Beneft of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus results from IMPROVE-IT (improved reduction of outcomes: Vytorin effcacy international trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib98","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2021.11.022_bib99","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1475-2840-12-S1-S3","article-title":"Statin diabetogenicity: guidance for clinicians","volume":"12","author":"Ray","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1567-5688(11)70888-1","article-title":"Pitavastatin: clinical effects from the LIVES study","volume":"12","author":"Teramoto","year":"2011","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"Yokote","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib102","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1185\/03007995.2013.874989","article-title":"Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies","volume":"30","author":"Chapman","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13340-011-0032-0","article-title":"Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients","volume":"2","author":"Yamazaki","year":"2011","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib104","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy - European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib106","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib107","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome the IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10557-016-6655-4","article-title":"Clinical profile of statin intolerance in the phase 3 GAUSS-2 study","volume":"30","author":"Cho","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"4(4):CD011748","key":"10.1016\/j.atherosclerosis.2021.11.022_bib109","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"28","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1056\/NEJMc1508222","article-title":"PCSK9 inhibitors and cardiovascular events","volume":"373","author":"JG","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib111","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14779072.2017.1348231","article-title":"Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?","volume":"15","author":"Stein","year":"2017","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib113","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib114","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib115","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib116","first-page":"1023","article-title":"Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data, Expert Opin","volume":"13","author":"Cicero","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"Lipids Research Clinics Program","year":"1984","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib118","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis","volume":"8","author":"Ross","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib119","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib120","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib121","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib122","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib123","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib124","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] Trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib127","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl\u2013intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin. Cardiol."},{"issue":"7(7):CD003177","key":"10.1016\/j.atherosclerosis.2021.11.022_bib129","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"18","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib130","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","author":"The ASCEND Study Collaborative Group","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib131","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib132","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib133","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib135","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib136","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib138","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib139","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib140","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib141","doi-asserted-by":"crossref","first-page":"A1373","DOI":"10.1016\/S0735-1097(14)61373-5","article-title":"Effects of alirocumab, A fully human monoclonal antibody to proprotein convertase subtilisin\/kexin type 9, ON lipoprotein particle concentrations determined BY nuclear magnetic resonance: substudy OF a randomized double-blind phase II clinical trial","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib142","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib143","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib144","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib145","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1161\/JAHA.116.003597","article-title":"Lipoprotein (a)-We know so much yet still have much to learn","volume":"5","author":"Banach","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib146","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","article-title":"Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists","volume":"5","author":"Davidson","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib147","series-title":"Combination Therapy in Dyslipidemia","author":"Banach","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib148","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"Van Der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib149","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk insights from the FOURIER trial","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib151","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib152","series-title":"Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification | Guidance","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib153","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.publhealth.19.1.55","article-title":"Hormone replacement therapy, heart disease, and other considerations","volume":"19","author":"Barrett-Connor","year":"1998","journal-title":"Annu. Rev. Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib154","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","article-title":"Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence","volume":"20","author":"Stampfer","year":"1991","journal-title":"Prev. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib155","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","article-title":"A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease","volume":"133","author":"Grodstein","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib156","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.atherosclerosis.2009.05.033","article-title":"Coronary heart disease and menopause management: the swinging pendulum of HRT","volume":"207","author":"Stevenson","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib157","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/GME.0b013e31829a64f9","article-title":"Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study","volume":"21","author":"Shufelt","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib158","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e6409","article-title":"Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial","volume":"345","author":"Schierbeck","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.10.005","article-title":"Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women","volume":"184","author":"Gregersen","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib160","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.diabres.2013.11.008","article-title":"Diabetes in the middle-East and North Africa: an update","volume":"103","author":"Majeed","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib161","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2019"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib162","author":"World Health Organization"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib163","first-page":"c120","article-title":"Chronic kidney disease in the Arab world: a call for action","volume":"121","author":"Farag","year":"2012","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib164","first-page":"150","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat. Clin. Pract. Endocrinol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2230-8210.91193","article-title":"Metabolic syndrome in the Middle East","volume":"16","author":"Sliem","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib167","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/IJGM.S160555","article-title":"Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East","volume":"11","author":"Alshamiri","year":"2018","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib168","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022186","article-title":"Quality of type 2 diabetes management in the states of the co-operation council for the Arab states of the Gulf: a systematic review","volume":"6","author":"Alhyas","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib170","doi-asserted-by":"crossref","DOI":"10.1177\/1557988319848577","article-title":"Prevalence of type 2 diabetes mellitus among men in the Middle East: a retrospective study","volume":"13","author":"Meo","year":"2019","journal-title":"Am. J. Men's Health"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib171","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/dc07-1117","article-title":"Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study","volume":"31","author":"Ilanne-Parikka","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib172","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib173","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"The ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib174","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/dme.12295","article-title":"Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review","volume":"31","author":"Ooi","year":"2014","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib175","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib176","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib177","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib178","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib179","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib180","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib181","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib182","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib183","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"Perspectives in renal medicine: the elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib184","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10157-015-1169-0","article-title":"Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients","volume":"20","author":"Sawai","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40620-015-0260-7","article-title":"Abdominal aortic calcification in patients with CKD","volume":"30","author":"Peeters","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib186","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014020173","article-title":"Subclinical atherosclerosis measures for cardiovascular prediction in CKD","volume":"26","author":"Matsushita","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib187","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2008.04.012","article-title":"Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease","volume":"52","author":"Garland","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000350580","article-title":"Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease","volume":"36","author":"Russo","year":"2013","journal-title":"Blood Purif."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib189","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2369-14-10","article-title":"Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients","volume":"14","author":"Pencak","year":"2013","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib191","article-title":"Kidney health in the Middle East","volume":"74","author":"Shaheen","year":"2010","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib192","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13690-018-0257-5","article-title":"Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study","volume":"76","author":"Raal","year":"2018","journal-title":"Arch. Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib193","first-page":"99","article-title":"The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors","volume":"22","author":"Safarinejad","year":"2009","journal-title":"J. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/shorts.2012.011150","article-title":"Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review","volume":"3","author":"Hassanien","year":"2012","journal-title":"JRSM Short Rep."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib195","series-title":"Kidney Int. Suppl.","first-page":"308","article-title":"Hypertension and chronic kidney disease in Turkey","author":"Sengul","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib196","first-page":"109","article-title":"Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a cross-sectional adult population-based study, Iran","volume":"8","author":"Khajehdehi","year":"2014","journal-title":"J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib197","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045304","article-title":"Incidence of chronic kidney disease and its risk factors, results of over 10 Year follow up in an Iranian cohort","volume":"7","author":"Tohidi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib198","first-page":"195","article-title":"End-stage renal disease in the Middle East: a systematic review and meta-analysis","volume":"12","author":"Malekmakan","year":"2018","journal-title":"Iran. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib199","first-page":"S2","article-title":"Incidence, prevalence, and treatment of end-stage renal disease in the Middle East","volume":"16","author":"Abboud","year":"2006","journal-title":"Ethn. Dis."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib200","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib201","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib205","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib206","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib207","first-page":"139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib208","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib209","author":"World Health Organization"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib210","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib211","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib212","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5001\/omj.2014.22","article-title":"Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population","volume":"29","author":"Al-Rasadi","year":"2014","journal-title":"Oman Med. J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib213","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib214","author":"European Medicines Agency"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib215","author":"Food and Drug Administration"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib216","first-page":"119","article-title":"Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib217","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib218","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib219","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib220","author":"European Medicines Agency"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib221","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib222","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib223","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/eurheartj\/ehv461","article-title":"Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome","volume":"36","author":"Mantel","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2008.06.011","article-title":"Cardiovascular morbidity and mortality in rheumatoid arthritis","volume":"121","author":"Gabriel","year":"2008","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib225","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National lipid association annual summary of clinical Lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib226","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00144","article-title":"History of gestational diabetes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women","volume":"8","author":"Shostrom","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib227","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib228","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006713","article-title":"Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women","volume":"6","author":"Ley","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib229","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/pds.4176","article-title":"Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss","volume":"26","author":"McGrogan","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib230","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","article-title":"The risks of statin use in pregnancy: a systematic review","volume":"10","author":"Karalis","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.10.001","article-title":"Duration of lactation and incidence of myocardial infarction in middle to late adulthood","volume":"200","author":"Stuebe","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib233","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.AOG.0000346884.67796.ca","article-title":"Duration of lactation and risk factors for maternal cardiovascular disease","volume":"113","author":"Schwarz","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib234","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/oby.21246","article-title":"Providing food to treat adolescents at risk for cardiovascular disease","volume":"23","author":"De Ferranti","year":"2015","journal-title":"Obesity"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2014.01.003","article-title":"Combined dyslipidemia in obese children: response to a focused lifestyle approach","volume":"8","author":"Pratt","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib236","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib237","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib238","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib239","first-page":"257","article-title":"Bempedoic acid (ETC-1002): a current review","volume":"36","author":"Saeed","year":"2018","journal-title":"Cardiol. Clin."},{"issue":"9(15):e016262","key":"10.1016\/j.atherosclerosis.2021.11.022_bib240","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Dai","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib241","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","article-title":"Anti-PCSK9 therapies for the treatment of hypercholesterolemia","volume":"13","author":"Hooper","year":"2013","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib242","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib243","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib244","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib245","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib246","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib247","article-title":"Olpasiran trials of cardiovascular events and LipoproteiN(a) reduction - DOSE finding study - full text view - ClinicalTrials.gov","year":"2020","journal-title":"U.S. Natl. Libr. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib248","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib249","article-title":"Assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with CVD - full text view - ClinicalTrials.gov","author":"gov","year":"2019","journal-title":"U.S. Natl. Libr. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib250","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.022_bib251","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:48:37Z","timestamp":1758156517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021014507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":250,"alternative-id":["S0021915021014507"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.022","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}